ZECCA, LUIGI
ZECCA, LUIGI
Istituto di Tecnologie Biomediche - ITB
A modern imaging investigation of neuromelanin extracted from the substantia nigra region of the human brain.
2005 Bush, Wd; Simon, Jd; Zucca, Fa; Zecca, L; Gargulio, J; Nemanich, Rj; Edwards, G
A proposed dual role of neuromelanin in the pathogenesis of Parkinson's disease
2006 Zecca, L; Zucca, Fa; Albertini, A; Rizzio, E; Fariello, Rg
A ROLE FOR NEURONAL MHC-I DISPLAY BY IN PARKINSON'S DISEASE?
2012 Cebrián C.; Zucca F.A.; Zecca L.; Loike J.D.; Sulzer D.
Activation of microglia by human neuromelanin is NF-kappaB dependent and involves p38 mitogen-activated protein kinase: implications for Parkinson's disease.
2003 Wilms, H; Rosenstiel, P; Sievers, J; Deuschl, G; Zecca, L; Lucius, R
Activation of microglia by neuromelanin: correlation of neuromelanin phagocytosis and degradation, reactive oxygen species production, and ventral midbrain neuron death.
2007 Faust R.; Phillips K.; Albertini A.; Zucca F.A.; Joset D.; Loike J.; Sulzer D.; Zecca L.
Aluminium in Alzheimer's disease: are we still at a crossroad?
2005 Gupta V.B.; Anitha S.; Hegde M.L.; Zecca L.; Garruto R.M.; Ravid R.; Shankar S.K.; Stein R.; Shanmugavelu P.; Jagannatha Rao K.S.
Amyloid beta and neuromelanin - Toxic or protective molecules? The cellular context makes the difference.
2007 Rao, Ksj; Zucca, Fa; Bellei, C; Panizza, M; Zecca, L
Amyloid beta and neuromelanin - Toxic or protective molecules? The cellular context makes the difference.
2007 Rao, Ksj; Hegde, Ml; Anitha, S; Musicco, M; Zucca, Fa; Turro, Nj; Zecca, L
Amyloid beta and neuromelanin--toxic or protective molecules? The cellular context makes the difference.
2006 Rao K.S.; Hegde M.L.; Anitha S.; Musicco M.; Zucca F.A.; Turro N.J.; Zecca L.
An XAS study of the sulfur environment in human neuromelanin and its synthetic analogs.
2010 Crippa, Pr; Eisner, M; Morante, S; Stellato, F; Vicentin, Fc; Zecca, L
Application of Pump-Probe Imaging Towards Chemical and Structural Characterization of Neuromelanin.
2016 Deb S.; Ferrari E.; Zucca F.A.; Zecca L.; Warren W.S.
Biosynthetic pathway to neuromelanin and its aging process
2012 Wakamatsu, K; Murase, T; Zucca, Fa; Zecca, L; Ito, S
Brain iron pathways and their relevance to Parkinson's disease.
2001 Berg D.; Gerlach M.; Youdim M.B.H.; Double K.L.; Zecca L.; Riederer P.; Becker G.
Challenges associated with metal chelation therapy in Alzheimer's disease.
2009 Hegde, Ml; Bharathi, P; Suram, A; Venugopal, C; Jagannathan, R; Poddar, P; Srinivas, P; Sambamurti, K; Rao, Kj; Scancar, J; Messori, L; Zecca, L; Zatta, P
Chemistry and biophysics of melanins
2011 Wakamatsu K.; Murase T.; Zucca F.A.; Zecca L.; Ito S.
Combined biochemical separation and INAA for the determination of iron and other metals in Neuromelanin of human brain Substantia Nigra
2001 Zecca L.; Tampellini D.; Costi P.; Rizzio E.; Giaveri G.; Gallorini M.
Contrast mechanisms associated with neuromelanin-MRI
2017 Trujillo P.; Summers P.E.; Ferrari E.; Zucca F.A.; Sturini M.; Mainardi L.T.; Cerutti S.; Smith A.K.; Smith S.A.; Zecca L.; Costa A.
Convenient Synthetic Method Of Putative Degradative Markers To Identify Various Catecholic Metabolites In Addition To Dopamine And Norepinephrine Incorporated In Neuromelanin.
2014 Tabuchi, K; Tanaka, H; Ojika, M; Zucca, Fa; Zecca, L; Ito, S; Wakamatsu, K
COVID-19 and possible links with Parkinson's disease and parkinsonism: from bench to bedside
2020 Sulzer D; Antonini A; Leta V; Nordvig A; Smeyne RJ; Goldman JE; AlDalahmah O; Zecca L; Sette A; Bubacco L; Meucci O; Moro E; Harms AS; Xu Y; Fahn S; Ray Chaudhuri K
DOPA pheomelanin is increased in nigral neuromelanin of Parkinson's disease
2023 Cai, W; Wakamatsu, K; Zucca, Fa; Wang, Q; Yang, K; Mohamadzadehonarvar, N; Srivastava, P; Tanaka, H; Holly, G; Casella, L; Ito, S; Zecca, L; Chen, X
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A modern imaging investigation of neuromelanin extracted from the substantia nigra region of the human brain. | 1-gen-2005 | Bush, Wd; Simon, Jd; Zucca, Fa; Zecca, L; Gargulio, J; Nemanich, Rj; Edwards, G | |
| A proposed dual role of neuromelanin in the pathogenesis of Parkinson's disease | 1-gen-2006 | Zecca, L; Zucca, Fa; Albertini, A; Rizzio, E; Fariello, Rg | |
| A ROLE FOR NEURONAL MHC-I DISPLAY BY IN PARKINSON'S DISEASE? | 1-gen-2012 | Cebrián C.; Zucca F.A.; Zecca L.; Loike J.D.; Sulzer D. | |
| Activation of microglia by human neuromelanin is NF-kappaB dependent and involves p38 mitogen-activated protein kinase: implications for Parkinson's disease. | 1-gen-2003 | Wilms, H; Rosenstiel, P; Sievers, J; Deuschl, G; Zecca, L; Lucius, R | |
| Activation of microglia by neuromelanin: correlation of neuromelanin phagocytosis and degradation, reactive oxygen species production, and ventral midbrain neuron death. | 1-gen-2007 | Faust R.; Phillips K.; Albertini A.; Zucca F.A.; Joset D.; Loike J.; Sulzer D.; Zecca L. | |
| Aluminium in Alzheimer's disease: are we still at a crossroad? | 1-gen-2005 | Gupta V.B.; Anitha S.; Hegde M.L.; Zecca L.; Garruto R.M.; Ravid R.; Shankar S.K.; Stein R.; Shanmugavelu P.; Jagannatha Rao K.S. | |
| Amyloid beta and neuromelanin - Toxic or protective molecules? The cellular context makes the difference. | 1-gen-2007 | Rao, Ksj; Zucca, Fa; Bellei, C; Panizza, M; Zecca, L | |
| Amyloid beta and neuromelanin - Toxic or protective molecules? The cellular context makes the difference. | 1-gen-2007 | Rao, Ksj; Hegde, Ml; Anitha, S; Musicco, M; Zucca, Fa; Turro, Nj; Zecca, L | |
| Amyloid beta and neuromelanin--toxic or protective molecules? The cellular context makes the difference. | 1-gen-2006 | Rao K.S.; Hegde M.L.; Anitha S.; Musicco M.; Zucca F.A.; Turro N.J.; Zecca L. | |
| An XAS study of the sulfur environment in human neuromelanin and its synthetic analogs. | 1-gen-2010 | Crippa, Pr; Eisner, M; Morante, S; Stellato, F; Vicentin, Fc; Zecca, L | |
| Application of Pump-Probe Imaging Towards Chemical and Structural Characterization of Neuromelanin. | 1-gen-2016 | Deb S.; Ferrari E.; Zucca F.A.; Zecca L.; Warren W.S. | |
| Biosynthetic pathway to neuromelanin and its aging process | 1-gen-2012 | Wakamatsu, K; Murase, T; Zucca, Fa; Zecca, L; Ito, S | |
| Brain iron pathways and their relevance to Parkinson's disease. | 1-gen-2001 | Berg D.; Gerlach M.; Youdim M.B.H.; Double K.L.; Zecca L.; Riederer P.; Becker G. | |
| Challenges associated with metal chelation therapy in Alzheimer's disease. | 1-gen-2009 | Hegde, Ml; Bharathi, P; Suram, A; Venugopal, C; Jagannathan, R; Poddar, P; Srinivas, P; Sambamurti, K; Rao, Kj; Scancar, J; Messori, L; Zecca, L; Zatta, P | |
| Chemistry and biophysics of melanins | 1-gen-2011 | Wakamatsu K.; Murase T.; Zucca F.A.; Zecca L.; Ito S. | |
| Combined biochemical separation and INAA for the determination of iron and other metals in Neuromelanin of human brain Substantia Nigra | 1-gen-2001 | Zecca L.; Tampellini D.; Costi P.; Rizzio E.; Giaveri G.; Gallorini M. | |
| Contrast mechanisms associated with neuromelanin-MRI | 1-gen-2017 | Trujillo P.; Summers P.E.; Ferrari E.; Zucca F.A.; Sturini M.; Mainardi L.T.; Cerutti S.; Smith A.K.; Smith S.A.; Zecca L.; Costa A. | |
| Convenient Synthetic Method Of Putative Degradative Markers To Identify Various Catecholic Metabolites In Addition To Dopamine And Norepinephrine Incorporated In Neuromelanin. | 1-gen-2014 | Tabuchi, K; Tanaka, H; Ojika, M; Zucca, Fa; Zecca, L; Ito, S; Wakamatsu, K | |
| COVID-19 and possible links with Parkinson's disease and parkinsonism: from bench to bedside | 1-gen-2020 | Sulzer D; Antonini A; Leta V; Nordvig A; Smeyne RJ; Goldman JE; AlDalahmah O; Zecca L; Sette A; Bubacco L; Meucci O; Moro E; Harms AS; Xu Y; Fahn S; Ray Chaudhuri K | |
| DOPA pheomelanin is increased in nigral neuromelanin of Parkinson's disease | 1-gen-2023 | Cai, W; Wakamatsu, K; Zucca, Fa; Wang, Q; Yang, K; Mohamadzadehonarvar, N; Srivastava, P; Tanaka, H; Holly, G; Casella, L; Ito, S; Zecca, L; Chen, X |